Thyroid disturbance in patients with chronic hepatitis C infection: A systematic review and meta-analysis

Journal of Gastrointestinal and Liver Diseases

Volumn 25, Issue 2, 2016, Pages 227-234

  Shen, Yi ^a   Wang, Xu Lin ^a   Xie, Jin Ping ^a   Shao, Jian Guo ^a   Lu, Yi Hua ^a   Zhang, Sheng ^a   Qin, Gang ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Anti thyroid antibody; HCV; Prevalence; Thyroid dysfunction

Indexed keywords

ALPHA INTERFERON; LIOTHYRONINE; MICROSOME ANTIBODY; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; ANTI-THYROGLOBULIN; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; IODIDE PEROXIDASE; IRON BINDING PROTEIN; THYROID MICROSOMAL ANTIBODIES; TPO PROTEIN, HUMAN;

AUTOIMMUNE THYROIDITIS; CHRONIC HEPATITIS C; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C VIRUS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOFLUORESCENCE; META ANALYSIS (TOPIC); PREVALENCE; QUALITY CONTROL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); ADULT; AGED; AUTOIMMUNITY; BLOOD; FEMALE; HEPATITIS C, CHRONIC; IMMUNOLOGY; MALE; META ANALYSIS; MIDDLE AGED; ODDS RATIO; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; BIOMARKERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; IODIDE PEROXIDASE; IRON-BINDING PROTEINS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84969931912     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 1999; 31: 369-376. doi: 10.1016/ S0168-8278(99)80239-6
2. Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One 2013; 8: e55364. doi: 10.1371/journal. pone.0055364
3. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998; 158: 1445-1448. doi: 10.1001/archinte.158.13.1445
4. Huang MJ, Wu SS, Liaw YF. Thyroid abnormalities in patients with chronic viral hepatitis. Hepatology 1994; 20: 1651-1652. doi: 10.1002/ hep.1840200650
5. Quaranta JF, Tran A, Regnier D, et al. High prevalence of antibodies to hepatitis C virus (HCV) in patients with anti-thyroid autoantibodies. J Hepatol 1993; 18: 136-138. doi: 10.1016/S0168-8278(05)80022-4
6. Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf) 1999; 50: 503-509. doi: 10.1046/j.1365-2265.1999.00686.x
7. Ganne-Carrie N, Medini A, Coderc E, et al. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. J Autoimmun 2000; 14: 189-193. doi: 10.1006/ jaut.1999.0360
8. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993; 18: 253-257. doi: 10.1002/ hep.1840180205
9. Mariotti S, Loviselli A, Murenu S, et al. High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment. J Endocrinol Invest 1999; 22: 55-63. doi: 10.1007/BF03345479
10. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015; 349: g7647. doi: 10.1136/bmj. g7647
11. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605. doi: 10.1007/s10654-010-9491-z
12. Zhang J, Shen Y, Cai H, Liu YM, Qin G. Hepatitis B virus infection status and risk of type 2 diabetes mellitus: A meta-analysis. Hepatol Res 2015; 45: 1100-1109. doi: 10.1111/hepr.12481
13. Chen ZX, Shao JG, Shen Y, et al. Prognostic implications of antibodies to soluble liver antigen in autoimmune hepatitis: A PRISMACompliant meta-analysis. Medicine 2015; 94: e953. doi: 10.1097/ MD.0000000000000953
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748. doi: 10.1093/jnci/22.4.719
15. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841-848. doi: 10.1002/hep.1840190407
16. Boadas J, Rodriguez-Espinosa J, Enriquez J, et al. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. J Hepatol 1995; 22: 611-615. doi: 10.1016/0168-8278(95)80216-9
17. Matsuda J, Saitoh N, Gotoh M, et al. High prevalence of antiphospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 1995; 90: 1138-1141.
18. Custro N, Montalto G, Scafidi V, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest 1997; 20: 374-380. doi: 10.1007/ BF03347987
19. Peoc'h K, Dubel L, Chazouilleres O, et al. Polyspecificity of antimicrosomal thyroid antibodies in hepatitis C virus-related infection. Am J Gastroenterol 2001; 96: 2978-2983. doi: 10.1111/j.1572-0241.2001.04671.x
20. Antonelli A, Ferri C, Fallahi P, et al. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM 2004; 97: 499-506. doi: 10.1093/qjmed/hch088
21. Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. The Am J Med 2004; 117: 10-13. doi: 10.1016/j. amjmed.2004.01.023
22. Floreani A, Betterle C, Carderi I, et al. Is hepatitis C virus a risk factor for thyroid autoimmunity? J Viral Hepat 2006; 13: 272-277. doi: 10.1111/j.1365-2893.2005.00699.x
23. Yang R, Shan ZY, Li YS, Fan CL, Li CY, Teng WP. Prevalence of thyroid autoantibodies in hepatitis C and hepatits B infection in China. Intern Med 2011; 50: 811-815. doi: 10.2169/internalmedicine.50.4870
24. Danilovic DL, Mendes-Correa MC, Chammas MC, Zambrini H, Barros RK, Marui S. Thyroid disturbance related to chronic hepatitis C infection: role of CXCL10. Endocr J 2013; 60: 583-590. doi: 10.1507/ endocrj.EJ12-0321
25. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841-848. doi: 10.1002/hep.1840190407
26. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012; 32: 85-92. doi: 10.1111/j.1478-3231.2011.02502.x
27. Arase Y, Ikeda K, Suzuki F, et al. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. J Gastroenterol 2004; 39: 1090-1094. doi: 10.1007/s00535-004-1483-x
28. Bourji K, Gatto M, Cozzi F, Doria A, Punzi L. Rheumatic and autoimmune thyroid disorders: a causal or casual relationship? Autoimmun Rev 2015; 14: 57-63. doi: 10.1016/j.autrev.2014.10.007
29. Choubey D, Moudgil KD. Interferons in autoimmune and inflammatory diseases: regulation and roles. J Interferon Cytokine Res 2011; 31: 857-865. doi: 10.1089/jir.2011.0101
30. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44: 635-642. doi: 10.1046/j.1365-2265.1996.751768.x
31. Munoz H, Arroyo J, Torres EA, et al. Response to combination therapy of interferon alfa-2b plus ribavirin in Hispanics with chronic hepatitis C. P R Health Sci J 2004; 23(2 Suppl): 61-67.
32. Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol 2012; 2012: 980942. doi: 10.1155/2012/980942
33. Akeno N, Blackard JT, Tomer Y. HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. J Autoimmun 2008; 31: 339-344. doi: 10.1016/j.jaut.2008.08.001
34. Antonelli A, Ferri C, Fallahi P, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid 2006; 16: 563-572. doi: 10.1089/ thy.2006.16.563
35. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355. doi: 10.7326/0003-4819-140-5-200403020-00010
36. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. doi: 10.1016/S0140-6736(01)06102-5
37. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev 2015; 14: 174-180. doi: 10.1016/j.autrev.2014.10.016